Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review

 


Get this Report



PayPal Verified Vendor

Rating

4.1 Star Rating for report Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review
4.1 / 5 stars rating
Pages: 32
Price: $125.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. 

Description

Nanjing Pharmaceutical Co Ltd (NPC) focuses on the distribution of a wide range of pharmaceutical products and other products. It provides a range of pharmaceutical supply chain services and health chain services. The company maintains distribution relationships with several companies in China. NPC also provides traditional Chinese medicine, logistics services and rent and property management. NPC provides its pharmaceuticals products to hospitals, pharmacies, community health institutions, chain pharmacies and rural township hospitals, clinics and other non-public medical institutions and commercial distribution enterprises. The company provides its services to Soviet Union; and Anhui, Jiangsu, Hubei, Sichuan, Yunnan and Fujian provinces covering several cities across China. NPC is headquartered in NanJing, Jiangsu, China. 

Similar Reports

Other reports that may be of interest...

Report... 05IC-GDPH82371FSASunwin Stevia International Inc (SUWN) - Financial and Strategic...Sep 2017
Report... 05IK-99236FFD-62D7-482B-B03C-28Mindray Medical International Limited - Strategy, SWOT and Corpo...May 2017
Report... 05IC-GDPH75695FSAShanghai RAAS Blood Products Co., Ltd. (002252) - Financial and ...Oct 2016
Report... 05IC-GDPH135710FSAZhejiang Huahai Pharmaceutical Co., Ltd. (600521) - Financial an...Oct 2016
Report... 05IC-GDPH202527FSAChina Animal Husbandry Industry Co., Ltd. (600195) - Financial a...Oct 2016
Report... 05IC-GDPH82070FSAChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (00099...Oct 2016
Report... 05IC-GDPH128259FSAAnhui Anke Biotechnology (Group) Co Ltd (300009) - Financial and...Nov 2017
Report... 05IC-GDPH138565FSAChina Medical System Holdings Ltd (867) - Financial and Strategi...Nov 2017
Report... 05IC-GDPH82265FSAHenan Lingrui Pharmaceutical Co Ltd (600285) - Financial and Str...Nov 2017
Report... 05IC-GDPH138889FSAShanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Financia...Nov 2017

Report Source Information

Supplied by: Research and Experts 
Date Published: 2017-10-17 

Report: Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review

 

Contents

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Nanjing Pharmaceutical Co Ltd - Key Facts 5
Nanjing Pharmaceutical Co Ltd - Key Employees 6
Nanjing Pharmaceutical Co Ltd - Major Products and Services 7
Nanjing Pharmaceutical Co Ltd - History 8
Nanjing Pharmaceutical Co Ltd - Locations And Subsidiaries 10
Head Office 10
Other Locations & Subsidiaries 10
Section 2 - Company Analysis 12
Nanjing Pharmaceutical Co Ltd - Business Description 12
Nanjing Pharmaceutical Co Ltd - SWOT Analysis 13
SWOT Analysis - Overview 13
Nanjing Pharmaceutical Co Ltd - Strengths 13
Nanjing Pharmaceutical Co Ltd - Weaknesses 14
Nanjing Pharmaceutical Co Ltd - Opportunities 15
Nanjing Pharmaceutical Co Ltd - Threats 16
Nanjing Pharmaceutical Co Ltd - Key Competitors 17
Section 3 - Company Financial Ratios 18
Financial Ratios - Capital Market Ratios 18
Financial Ratios - Annual Ratios 19
Performance Chart 22
Financial Performance 22
Financial Ratios - Interim Ratios 23
Financial Ratios - Ratio Charts 24
Section 4 - Company's Lifesciences Financial Deals and Alliances 25
Nanjing Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
Nanjing Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
Nanjing Pharmaceutical Co Ltd, Recent Deals Summary 27
Section 5 - Appendix 28
Methodology 28
Ratio Definitions 28
About GlobalData 32
Contact Us 32
Disclaimer 32
 

List of Tables

List of Tables
Nanjing Pharmaceutical Co Ltd, Key Facts 5
Nanjing Pharmaceutical Co Ltd, Key Employees 6
Nanjing Pharmaceutical Co Ltd, Major Products and Services 7
Nanjing Pharmaceutical Co Ltd, History 8
Nanjing Pharmaceutical Co Ltd, Subsidiaries 10
Nanjing Pharmaceutical Co Ltd, Key Competitors 17
Nanjing Pharmaceutical Co Ltd, Ratios based on current share price 18
Nanjing Pharmaceutical Co Ltd, Annual Ratios 19
Nanjing Pharmaceutical Co Ltd, Annual Ratios (Cont...1) 20
Nanjing Pharmaceutical Co Ltd, Annual Ratios (Cont...2) 21
Nanjing Pharmaceutical Co Ltd, Interim Ratios 23
Nanjing Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
Nanjing Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
Nanjing Pharmaceutical Co Ltd, Recent Deals Summary 27
Currency Codes 28
Capital Market Ratios 28
Equity Ratios 29
Profitability Ratios 29
Cost Ratios 30
Liquidity Ratios 30
Leverage Ratios 31
Efficiency Ratios 31
 

List of Figures

List of Figures
Nanjing Pharmaceutical Co Ltd, Performance Chart (2012 - 2016) 22
Nanjing Pharmaceutical Co Ltd, Ratio Charts 24
Nanjing Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
Nanjing Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 26
 

Scope

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

 

Classification

Language Code: EN 
Region: China 
Report Type: Company Reports 
Industry: Life Sciences 
Sector: Life Sciences 
Pages: 32 

Companies Featured

Zhejiang Hisun Pharmaceutical Co Ltd Sinopharm Group Co Ltd Sihuan Pharmaceutical Holdings Group Ltd Jiangsu Hengrui Medicine Co Ltd Fosun International Ltd Dalian Dashang Group Co., Ltd. Chinese Meheco Corp Bailian Group Co., Ltd.

 

Reasons to buy this report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 

Similar Reports

Other reports that may be of interest...

Report... 05IC-GDPH82371FSASunwin Stevia International Inc (SUWN) - Financial and Strategic...Sep 2017
Report... 05IK-99236FFD-62D7-482B-B03C-28Mindray Medical International Limited - Strategy, SWOT and Corpo...May 2017
Report... 05IC-GDPH75695FSAShanghai RAAS Blood Products Co., Ltd. (002252) - Financial and ...Oct 2016
Report... 05IC-GDPH135710FSAZhejiang Huahai Pharmaceutical Co., Ltd. (600521) - Financial an...Oct 2016
Report... 05IC-GDPH202527FSAChina Animal Husbandry Industry Co., Ltd. (600195) - Financial a...Oct 2016
Report... 05IC-GDPH82070FSAChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (00099...Oct 2016
Report... 05IC-GDPH128259FSAAnhui Anke Biotechnology (Group) Co Ltd (300009) - Financial and...Nov 2017
Report... 05IC-GDPH138565FSAChina Medical System Holdings Ltd (867) - Financial and Strategi...Nov 2017
Report... 05IC-GDPH82265FSAHenan Lingrui Pharmaceutical Co Ltd (600285) - Financial and Str...Nov 2017
Report... 05IC-GDPH138889FSAShanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Financia...Nov 2017

Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review

Report 05IC-GDPH227948FSA has a rating of 81 percent
Figure of merit assessment for report 05IC-GDPH227948FSA

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1373

Taxonomy Location

The taxonomy on the left shows the ancestors of the China node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

China

China is the largest tading economy in the world and has experienced growth rates averaging 10% over the past 30 years. Key exports include electrical and other machinery, including data processing equipment, apparel, textiles, iron and steel, optical and medical equipment totalling  $2.021 trillion(est.) in 2012.  

At the recent Davos economic forum Chinese representatives and commentators acknowledged that the Chinese economy is slowing down from the unsustainable double digit growth rate to an expected growth rate of 7.5% in 2014. China now wants to focus on quality growth taking account of social issues, poverty, social issues and corruption.

Other imbalances in the Chinese economy are too much savings and not enough private consumption . Reforms need to be implemented soon to address this imbalance. Such reforms could slow growth to 6% but the government doesn't wish to drop below 7% growth. The policy of growing fixed investments such as property, infrastructure and State Owned Enterprises (SOE's) has benefitted many and has been open to much corruption and there will probably be objections to slowing growth in these areas.

Reform of the SOE's is seen by many experts as crucial to the future success of the economy in the next five to ten years. Proper corporate governance and international benchmarking is seen as necessary for the success of global enterprises.

Other issues which require attention are the high levels of debt amongst local governments and the high price of property. Steps need to be taken to avoid a property burst. 

Growth rates in traditional manufacturing sectors such as cement, steel, glass has been slowing down while growth has been accelerating in healthcare and IT. Market forces seem to be rebalancing and pushing the economy in the right direction. Companies such as Alibaba, Lenovo and Baidu are now leading forces in the global technology sector. 

One of the most exciting aspects of the Chinese economy is the well educated workforce with almost 7 million graduates entering the workforce each year. This high skill level will help to speed up the new economy and facilitate the necessary changes on multiple levels (environment, social, demographic).

Concencus on reform is coming from the very top levels of Chinese government and at grass roots level however the bureaucrats in the middle have much to loose and will object. A positive outcome on reform is expected by many experts on the Chinese economy.

Researchandexperts.com is a  leading source of market research on China.

Useful Links

OECD Overview of China

China and the World Bank

China

Eastern Asia

Region

 

Asia

Continent

Asia

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 205

Taxonomy Location

The taxonomy on the left shows the ancestors of the Life Sciences node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review

 

Item Code: 05IC-GDPH227948FSA

 
Licence: Single User
Price: $125.00
 
VAT: 0.0% 
Total: $125.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.79044s]

--